Aquestive Therapeutics Balance Sheet Health
Financial Health criteria checks 1/6
Aquestive Therapeutics has a total shareholder equity of $-45.4M and total debt of $31.1M, which brings its debt-to-equity ratio to -68.5%. Its total assets and total liabilities are $110.0M and $155.4M respectively.
Key information
-68.5%
Debt to equity ratio
US$31.13m
Debt
| Interest coverage ratio | n/a |
| Cash | US$77.89m |
| Equity | -US$45.42m |
| Total liabilities | US$155.38m |
| Total assets | US$109.96m |
Recent financial health updates
Recent updates
Aquestive: Rare Opportunity With Dual Platform Strategy
Nov 05Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Sep 07
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aug 20Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Financial Position Analysis
Short Term Liabilities: AQST has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AQST has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AQST has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AQST's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AQST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AQST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.